DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award

Key Facts

Status: Forecasted

Posted date: May 4, 2026

Archive date: August 7, 2026

Close date: July 8, 2026

Opportunity ID: 362211

Opportunity number: HT942526BCRPTBCCDA

Opportunity category: Discretionary

Agency name: Dept. of the Army -- USAMRAA

Agency code: DOD-AMRAA

Award floor: $0

Award ceiling: $0

Cost sharing required: No

Funding Instrument Types
  • Cooperative Agreement
Category of Funding Activity
  • Science and Technology and other Research and Development
Eligible Applicants
  • Unrestricted
Tools
Categories (use these for quoted searches)
  • agency_code:dod_amraa
  • category_of_funding_activity:science_and_technology_and_other_research_and_development
  • cost_sharing_or_matching_requirement:false
  • eligible_applicants:unrestricted
  • funding_instrument_type:cooperative_agreement
  • opportunity_category:discretionary
  • status:forecasted
Description

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Development Award provides successful applicants the time and resources needed to bring investigators and breast cancer consumer advocates together to establish a consortium framework and conduct preliminary research in support of an application to a future, full BCRP Transformative Breast Cancer Consortium Award (pending availability of funds). All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.Distinctive Features:· This is a development award and is a separate award mechanism from the full FY26 BCRP Transformative Breast Cancer Consortium Award (HT942526BCRPTBCCA). For FY26, investigators may be named as Consortium Director on an application submitted to either (but not both) of these award mechanisms.· Breast cancer consumer advocates must be active participants in the development and execution of the FY26 BCRP TBCCDA.

DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Development Award provides successful applicants the time and resources needed to bring investigators and breast cancer consumer advocates together to establish a consortium framework and conduct preliminary research in support of an application to a future, full BCRP Transformative Breast Cancer Consortium Award (pending availability of funds). All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.Distinctive Features:· This is a development award and is a separate award mechanism from the full FY26 BCRP Transformative Breast Cancer Consortium Award (HT942526BCRPTBCCA). For FY26, investigators may be named as Consortium Director on an application submitted to either (but not both) of these award mechanisms.· Breast cancer consumer advocates must be active participants in the development and execution of the FY26 BCRP TBCCDA.
[Forecasted] DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award
Forecasted
Dept. of the Army -- USAMRAA
Science and Technology and other Research and Development
Cooperative Agreement
Unrestricted
2026-05-04